Bedrijfsoverzicht
Exicure, Inc. is a biotechnology entity that previously concentrated its operational efforts on developing nucleic acid therapies designed to target ribonucleic acid against validated biological targets. Operating within the broader healthcare sector and the specific sub-sector of biotechnology, the company functions in a high-risk environment where research and development costs typically exceed immediate revenue generation. The firm maintains a relatively small organizational scale with a total market capitalization of $24.07M and an active workforce consisting of only eight employees. These valuation and staffing metrics indicate that Exicure operates as a micro-cap entity with minimal revenue generation, reflecting a position typical for early-stage or development-focused biotechnology firms that have not yet commercialized their primary assets. The absence of significant current operations further contextualizes the market cap as a reflection of potential future value rather than established cash flows or sales performance.
Financiële gezondheid
The company reports no revenue figures for the trailing twelve-month period, while recording a net income of $-4,946,000 and an EBITDA of $-9,875,000. The absence of revenue combined with substantial negative net income reveals a cost structure driven entirely by operating expenses and research expenditures rather than commercial sales activity. Free cash flow stands at $-4,212,750, indicating that the company is currently burning cash without generating operational liquidity to fund its activities independently. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not generated enough revenue to cover its variable or fixed costs to produce a positive contribution margin. In terms of capital structure, Exicure holds $3.75M in cash against $176,000 in debt, resulting in a debt-to-equity ratio of 4.48. Despite the low absolute debt level, the high debt-to-equity ratio suggests a leveraged profile relative to the company's equity base, though the significant cash reserve provides a buffer against short-term obligations. The current ratio is 1.19, indicating that the company possesses sufficient current assets to cover its current liabilities, suggesting adequate short-term liquidity management despite the lack of profitability. Return on equity stands at -92.5% and return on assets at -43.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the lack of revenue streams to generate returns.
Waarderingsbeoordeling
Exicure presents a valuation profile characterized by negative multiples, with a trailing P/E ratio listed as N/A and a forward P/E of -4.91. The discrepancy between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in continued losses, making traditional earnings-based valuation multiples inapplicable for assessing intrinsic value at this stage. The price-to-book ratio is 6.13, indicating that the market values the company at a significant premium over its book value, a common phenomenon in biotechnology where intellectual property potential outweighs current asset valuation. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of sales, and an EV/EBITDA of -2.08, further underscore the inability to value the firm using standard profitability or sales-based multiples. The stock has traded between a 52-week high of $12.65 and a 52-week low of $3.10, meaning the current price sits somewhere within a range where the equity has demonstrated high volatility. With a beta of 4.01, the stock exhibits extreme price volatility relative to the broader market, moving with four times the intensity of the S&P 500.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, preventing a direct comparison of earnings expansion relative to sales growth. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available earnings to fund operations rather than distributing them to shareholders. The company reinvests its entire financial resources into growth initiatives, specifically continuing its focus on nucleic acid therapies rather than providing income to investors. The overall growth and income profile is defined by a complete lack of historical sales growth data and an absence of dividend income, relying entirely on the potential future commercialization of its therapeutic assets.